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S164 Oral PresentationsResults: In the related group we observed 8 graft failures (GF): 5
pts had an HLA identical sibling (HLA id sib) donor and 3 had
other related (OR) donors. In this group, 3 pts had primary GF
and received a 2nd HSCT, but just one is alive. Five pts had second-
ary GF, in a median of 149 days (156-365) after the first transplant.
Three had HLA id sib and two OR donors. Four pts received a 2nd
HSCT using the same donor and 2 are alive. In the unrelated
group we had 11 BM transplants (10pts had primary GF and one
had a secondary GF) and 12 UCB transplants (all pts had primary
GF). Only one pt in this group is alive after 2nd transplant (BM). In
univariate analysis, the variables that influenced the cumulative in-
cidence (CI) of GF were the use of unrelated versus related donor
(30  10%) and transfusions (. 25 units) 30% x 6% The use of
fludarabine was associated with lower CI of GF in the unrelated
group.
Conclusions: Graft failure is a very serious complication after
HSCT and in this study, it was more frequently associated with
the use of unrelated mismatched donors, more transfunded pts and
without fludarabine in the conditioning in the group of UD.New
conditionings and reduction in time to find an unrelated donor
may be alternatives to reduce GF in FA patients.26
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We recently demonstrated that early post-transplant vaccination
of patients with myeloid leukemia with irradiated autologous tu-
mor cells, virally transduced to express the potent cytokine adju-
vant GM-CSF, is a promising approach to enhance anti-
leukemia immunity with minimal toxicity (Ho et al, PNAS
2009). Chronic lymphocytic leukemia (CLL) is an ideal disease
to extend this treatment approach since it is incurable by conven-
tional chemotherapy, is sensitive to graft-versus-leukemia effects,
and has readily harvestable leukemia cells. However, viral trans-
duction of lymphoid cells is inefficient, and GM-CSF-based cellu-
lar vaccines have thus far been unavailable for CLL. To address
this limitation, we manufactured K562 cells engineered to secrete
high and consistent levels of GM-CSF (10 micrograms GM-
CSF/106 cells/24 hours), and initiated a phase I study to test the
effects of a post-transplant vaccine consisting of 1 x 107 irradiated
autologous CLL cells together with an equal number of irradiated
bystander GM-K562 cells. CD19 + CD5 +CLL cells were har-
vested from patient peripheral blood or marrow and banked prior
to salvage chemotherapy. To date, we have enrolled 13 patients
with CLL, who had experienced a median of 4 prior therapies
(range 2-8). Median CLL marrow involvement at transplant was
10% (range \5-50%). Patients were conditioned with a fludara-
bine/busulfex-based reduced-intensity regimen prior to infusion
of peripheral blood stem cells from a matched related (4) or unre-
lated (9) donor, and received tacrolimus as GvHD prophylaxis
throughout the vaccination period. Starting on day 30-45, vaccines
were administered as a cycle of 6 vaccines (s.c./i.d., every week x 3,
then every 2 weeks x 3). Ten of 13 patients received at least one
vaccine, and 7 of 10 received 3 or more vaccines. Three of 13 de-
veloped graft-versus-host disease (GvHD) prior to day 45, preclud-
ing vaccination. Four of the 10 vaccinated subjects developed grade
II GvHD. None experienced unexpected toxicities to vaccines. At
a median follow-up of 1 year (range 0.5-2 years), 9 of 10 vaccinated
subjects remain free of disease, and 1 patient remains in partial re-
mission. Our studies reveal that reduced intensity transplant fol-
lowed by early CLL/GM-K562 vaccination is well-tolerated and
does not increase the expected rate of GvHD. Early clinical results
are promising and ongoing studies are assessing the effects of the
vaccination on the induction of immunity against recipient CLL
cells.AUTOIMMUNE DISEASE
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DENIALS OF TREATMENT COVERAGE BY HEALTH INSURANCE CARRIERS
RESTRICT PATIENT RECRUITMENT ON A RANDOMIZED CLINICAL TRIAL:
EXPERIENCE OF 95 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) EN-
ROLLED IN THE SCOT (SCLERODERMA: CYCLOPHOSPHAMIDE OR
TRANSPLANTATION) TRIAL
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Background: Although health insurance coverage decisions can re-
strict recruitment on clinical trials, there are surprisingly few pub-
lished data measuring this effect.
Methods: Subjects with poor prognosis SSc were enrolled on the
ongoing SCOT trial comparing cyclophosphamide with autologous
stem cell transplant. Insurance submissions included evaluations
from SCOT rheumatology and BMT physicians, screening data,
protocol and consents approved by local IRBs, NIH and FDA and
supporting publications. Specific entry criteria and treatments are
further detailed at the study website (www.sclerodermatrial.org).
Results: Requests for coverage for 95 SCOT eligible patients (pts)
were submitted from the 7 BMT centers listed above to 49 health in-
surance plans (54 pts to 28 Blue Cross Blue Shield plans; 26 pts to 12
other commercial plans; and 15 pts to 9 governmental plans). At ini-
tial submission, 44 pts were approved and 51 (54%) were denied cov-
erage. Of the 51 subjects denied coverage, 15 did not appeal and
became ineligible for treatment randomization while 36 filed a first
appeal. Of these 36 pts, 23 were again denied while 13 (36%) were
approved on outside review. Of the 23 pts with first appeal denials,
10 did not file another appeal. Of the 13 filing a second appeal, 7
(54%) were approved. In total, 64/95 (67%) pts were approved on
initial or appeal reviews. The majority of denials were determina-
tions that protocol therapies were ‘‘experimental or investigational’’,
despite supplied published evidence that both SSc treatments yield
promising results (NEJM 2006; 354:2655 and Blood 2007;
110:1388). Time from application through appeals varied from 2-7
months, and for several subjects PFTs further declined during review
making them ineligible for randomization. Approval rates (initial ap-
plication + appeals) varied by carrier: 23/26 (88%) for non-Blue
plans; 33/54 (61%) for Blue plans; and 8/15 (53%) for governmental
plans. Remarkably, within the same plan, payment decisions for the
same protocol and the same type of pt were inconsistent or persistent
in denial despite reversals on outside expert review for prior pts.
Conclusions:Health insurer payment decisions can be arbitrary and
inconsistent. This is the first study with evidence that some insurers
delay and restrict patient access and recruitment on an NIH-spon-
sored randomized trial, thereby impeding clinical research and the
evidence needed to advance health care in America. Supported by
NIH award AI-05419.
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AN ALGORITHMIC APPROACH TO EVALUATE THE OPTIMAL USE OF
PLERIXAFOR (MOZOBIL) FOR AUTOLOGOUS HEMATOPOIETIC PE-
RIPHERAL BLOOD STEM CELL (PBSC) COLLECTIONS BASED ON PERIPH-
ERAL CIRCULATING CD34 COUNTS AND DAY ONE COLLECTION YIELD IN
PATIENTSWITHMULTIPLE MYELOMA (MM) AND LYMPHOMA (NHL, HD)
Abhyankar, S.H.1, Aljitawi, O.1, Ganguly, S.1, McGuirk, J.P.1,
DeJarnette, S.D.2,Merkel,D.A.2 1TheUniversity of KansasMedicalCen-
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Autologous PBSC transplantation is used as treatment for patients
with MM and lymphoma, but 25-35% of these patients fail to mobi-
lize a sufficient number of PBSC in the first mobilization attempt.
Plerixafor with G-CSF is now often used as a salvage mobilizing reg-
imen in patients failing first attempt with G-CSF alone.
